Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older  by Jackson, Lisa A. et al.
I
o
r
a
L
K
a
b
c
d
e
f
a
A
R
R
A
A
K
A
P
R
g
c
r
e
0
hVaccine 31 (2013) 3594– 3602
Contents lists available at SciVerse ScienceDirect
Vaccine
j our nal homep ag e: www.elsev ier .com/ locate /vacc ine
nﬂuence  of  initial  vaccination  with  13-valent  pneumococcal  conjugate  vaccine
r  23-valent  pneumococcal  polysaccharide  vaccine  on  anti-pneumococcal
esponses  following  subsequent  pneumococcal  vaccination  in  adults  50  years
nd  older
isa  A.  Jacksona,∗,  Alejandra  Gurtmanb, Martin  van  Cleeff c, Robert  W.  Frenckd, John  Treanore,
athrin  U.  Jansenb,  Daniel  A.  Scottb, Emilio  A.  Eminib, William  C.  Gruberb,  Beate  Schmoele-Thomaf
The Group Health Research Institute, Group Health, Seattle, Washington, United States
Pﬁzer Inc, Pearl River, New York, United States
Triangle Medical Research Associates, Cary, North Carolina, United States
Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
University of Rochester Medical Center, Rochester, New York, United States
Pﬁzer GmbH, Berlin, Germany
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 4 January 2013
eceived in revised form 11 April 2013
ccepted 26 April 2013
vailable online 18 May 2013
eywords:
dult
neumococcal conjugate vaccine
ecall responses
a  b  s  t  r  a  c  t
Background:  Unlike  free  polysaccharide  vaccines,  pneumococcal  polysaccharide  conjugate  vaccines
(PCVs)  induce  a T cell-dependent  immune  response  and  have  the  potential  to provide  an  extended
duration  of  protection  with  repeated  vaccinations.
Methods:  This  was  an  extension  of  a  previous  study  in  pneumococcal  vaccine-naïve  adults  aged  50–64
years in which  adults  60–64  years  of  age  were  given  13-valent  PCV  (PCV13)  or  23-valent  pneumococ-
cal  polysaccharide  vaccine  (PPSV23)  and  adults  aged  50–59  were  given  PCV13.  In  this  follow  up  study
conducted  about  4 years  later,  the  60–64  year  olds  initially  given  PCV13  received  PCV13  or PPSV23,  and
those initially  given  PPSV23  received  another  PPSV23.  All adults  aged  50–59  years  were  re-vaccinated
with  PCV13.  Anti-pneumococcal  opsonophagocytic  activity  (OPA)  titers  were  measured  before  and  1
month  after  vaccination.
Results: A  second  PCV13  given  about  4 years  after  a  ﬁrst vaccination  induced  OPA  titers  that were signiﬁ-
cantly higher  than  those  following  the  initial  vaccination  for  7  of  13  serotypes  in the  older  group,  and  6 of
13 serotypes  in  the  younger  group,  and  responses  to  the  remaining  serotypes  were  largely  non-inferior.
In contrast,  OPA  titers  following  revaccination  with  PPSV23  were  statistically  signiﬁcantly  lower  for  9 of
the 13  serotypes,  and non-inferior  for  the  remaining  serotypes,  when  compared  to the  responses  to  the
ﬁrst PPSV23.  OPA  titers  in  the  older  adults  who  received  PPSV23  after  initial  PCV13  were  signiﬁcantly
higher  than  those  following  a  ﬁrst  PPSV23  for  10 of the  13  serotypes.
Conclusion:  In  adults  50  to  64  years  of age,  initial  vaccination  with  PCV13  establishes  an  immune  state
that results  in  recall  anti-pneumococcal  responses  upon  subsequent  vaccination  with  either  conjugated
or  free  polysaccharide  vaccine.  In  contrast,  initial  vaccination  with  PPSV23  results  in an  immune  state
in which  subsequent  PPSV23  administration  yields  generally  lower  responses  compared  with  the initial
responses.
© 201
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accinations received as part of the initial study are shown in the striped boxes [5
neumococcal polysaccharide vaccine.
. Introduction
The incidence and mortality of pneumococcal disease in adults
ncrease with advancing age [1,2]. A 23-valent pneumococcal vac-
ine containing free (unconjugated) polysaccharides (PPSV23) has
een available for 30 years and a single vaccination is recom-
ended for adults ≥65 years and for younger adults with certain
hronic medical conditions or other indications [2]. Revaccina-
ion is not routinely indicated in part due to the diminished
mmune responses that have been observed following revacci-
ation, which may  be due to the T cell independent nature
f the immune response [2,3]. In contrast to PPSV23, the 13-
alent pneumococcal conjugate vaccine (PCV13) was designed to
ngender T cell-dependent immunity, inducing a recall response
n subsequent bacterial exposure or revaccination with the
otential to signiﬁcantly prolong the protection afforded by the
accine.[4]
A previous clinical study of pneumococcal vaccine-naïve adults
0 through 64 years of age evaluated the functional opsonophago-
ytic activity (OPA) anti-pneumococcal immune responses elicited
y a ﬁrst vaccination with PCV13 or PPSV23. PCV13 was  immuno-
enic and, in adults 60–64 years of age that were randomized to
eceive PCV13 or PPSV23, PCV13 elicited signiﬁcantly higher OPA
iters than those elicited by PPSV23 for 9 of 12 serotypes common
o both vaccines. Adults 50–59 years of age all received PCV13, and
ad generally higher OPA titers than observed in adults 60–64 years
f age who received PCV13 [5].reviations: PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent
This follow-up study was  conducted 3.5–4 years after the pre-
vious study in order to evaluate the immune responses to a second
PCV13 and to a second PPSV23, and to determine the inﬂuence
of initial PCV13 immunization on the responses to a subsequent
PPSV23 vaccination in the adults 60–64 years of age who  received
PCV13.
2. Methods
2.1. Study design and populations
This was an extension of a previous study in pneumococcal
vaccine-naïve adults 50 through 64 years of age, conducted at
23 medical centers in the United States [5]. Both studies were
undertaken in accordance with the Declaration of Helsinki and
Good Clinical Practice [6,7]. In the initial study, adults 60–64
years of age were randomly assigned with equal probability
to receive PCV13 or PPSV23 and those 50–59 years of age
received open label PCV13. In this extension study conducted
3.5–4 years after the start of the previous study, informed con-
sent was  obtained as for a new study and adults in the 60–64
year old age group who had initially received PCV13 were ran-
domized 1:1 to receive PCV13 or PPSV23, and those who had
received PPSV23 received another PPSV23 vaccination. Adults
in the 50–59 year old age group received a second PCV13
(Fig. 1).
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Table 1
Baseline characteristics.
Characteristic 60–64 Year age group 50–59 Year age group
PCV13/PCV13 N = 108 PCV13/PPSV23 N = 108 PPSV23/PPSV23 N = 189 PCV13/PCV13 N = 214
Female, % 57.4 50.0 64.0 63.1
Race,  %
White 98.1 96.3 94.7 94.9
Black 0.0 0.9 1.6 3.7
Asian 0.0 0.9 0.5 1.4
Other 0.9 0.0 2.1 0.0
Indian or Alaska Native 0.9 1.9 0.5 0.0
Native Hawaiian or Other Paciﬁc Islander 0.0 0.0 0.5 0.0
Hispanic or Latino, % 0.9 2.8 3.2 0.0
61.7 
3.7 
65.3 
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fMean age at vaccination 1, years (SD) 61.6 (1.4)
Time  since vaccination 1, years (SD) 3.7 (0.1) 
Mean  age at vaccination 2, years (SD) 65.3 (1.4) 
The study populations for both studies included persons with
table pre-existing underlying chronic conditions (e.g., cardiovas-
ular, pulmonary, renal, liver diseases including alcoholic liver
isease and alcoholism, and diabetes mellitus). Disease had to be
table, deﬁned as not requiring signiﬁcant change in therapy or hos-
italization for worsening disease 12 weeks prior to vaccination.
articipants were excluded if they had serious chronic disorders
ncluding metastatic malignancy, severe chronic obstructive pul-
onary disease requiring supplemental oxygen, end-stage renal
isease with or without dialysis, clinically unstable cardiac disease,
mpaired immune function, or had previously received a PPSV23
ose or any prior PCV.
Non-study medications were permitted. Licensed vaccines,
xcept pneumococcal vaccines, could be given according to local or
ational recommendations, and could be administered concomi-
antly. Receipt of inﬂuenza vaccine was permitted, if it was  given
t least 14 days before or after study vaccination.
Clinic visits occurred at vaccination and 1 month (29–43 days)
fter vaccination with a telephone visit for a safety assessment at 6
onths after vaccination. Blood samples were obtained before and
 month after vaccination.
.2. Vaccines and administration
PCV13 (Prevnar 13/Prevenar 13®, Wyeth Vaccines; Lot Num-
er 7-5095-010A) contains polysaccharides of pneumococcal
erotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, and 23F
ndividually conjugated to a nontoxic mutant form of diphtheria
oxin cross-reactive material 197 (CRM197). Each 0.5 mL  dose con-
ains 2.2 g of each serotype, except type 6B, which is included
t 4.4 g. Each dose is formulated in 5.0 mM succinate and 0.85%
odium chloride at pH 5.8 with 0.125 mg  aluminum as aluminum
hosphate and 0.02% polysorbate 80. The vaccine is supplied in
ingle-dose syringes without preservatives and stored at 2–8 ◦C.
PPSV23 (Pneumovax 23®, Merck & Company, Inc; Lot Number
08071-003L) consists of a puriﬁed capsular polysaccharide from
2 of the serotypes included in PCV13 (all except 6A), as well as
1 additional serotypes (2, 8, 9 N, 10A, 11A, 12F, 15B, 17F, 20, 22F,
nd 33F). The vaccine is formulated to contain 25 g of each of the
3 puriﬁed polysaccharide serotypes per 0.5 mL  dose of vaccine,
ontains phenol as a preservative and stored at 2–8 ◦C.
Vaccines were administered by intramuscular injection in the
eltoid using 25 G 1 in. needles.
.3. Study objectivesIn the older age group, the primary study objective was  to evalu-
te the response to PPSV23 after an initial dose of PCV13 or PPSV23
or the 12 serotypes common to both vaccines and for serotype 6A(1.3) 61.6 (1.4) 54.4 (2.9)
(0.1) 3.7 (0.1) 3.5 (0.1)
(1.4) 65.3 (1.4) 57.9 (2.9)
which is unique to PCV13.Secondary objectives were to evaluate
the ability of PCV13 to maintain or enhance OPA responses when
given 3.5–4 years after an initial dose of PCV13 in both age groups,
and describe the immune responses following 2 consecutive doses
of PPSV23 in the older age group for the 12 serotypes common to
both vaccines and for serotype 6A. Additionally, various immune
response comparisons were performed as described in the Results
section.
2.4. Analysis populations
The evaluable immunogenicity population was the primary
population for immunogenicity analyses and consisted of eligible
subjects who  had at least one valid and determinate assay result in
this extension study, received both study vaccines as assigned and
no prohibited vaccines, and had no other major protocol violation.
2.5. Immunogenicity assessments
Primary endpoints were the functional antibacterial OPA titers
for the 13 serotypes in PCV13 measured using serotype-speciﬁc
validated OPA assays in samples obtained immediately before and
approximately 1 month after each vaccination [8].
2.6. Safety assessments
Participants recorded local reactions (redness, swelling, pain
and limitation of arm movement of the injected arm), and systemic
events (chills, fatigue, headache, vomiting, decreased appetite,
rash, new generalized muscle pain, aggravated generalized muscle
pain, new generalized joint pain, and aggravated generalized joint
pain), and oral temperature in an electronic diary on the evening
of vaccination and for the next 13 days. Adverse events (AEs) were
collected from enrollment through the month 1 postvaccination
visit, serious adverse events (SAEs) from enrollment through the
month 6 follow-up phone contact, and deaths through the end of
the study.
2.7. Statistical analysis
2.7.1. Sample size considerations
All subjects who received the ﬁrst vaccination and satisﬁed eli-
gibility criteria to receive a second vaccination were included in the
analyses. No formal power calculation was done.2.7.2. Immunogenicity analyses
All analyses were descriptive and were done using the SAS soft-
ware package. The non-inferiority criterion used in the previous
study was  applied in this study. No imputations were done for
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issing data. For the comparison of post-vaccination OPA GMTs
etween vaccine groups or sequences, the 2-sided 95% conﬁ-
ence interval (CI) on the geometric mean ratio (GMR) for each
erotype was calculated (back-transformed 95% CI for mean dif-
erence on the logarithmic scale computed using the Student t
istribution). For comparisons within a vaccine sequence, anal-
ses were performed using data only from those subjects who
ad OPA assessments after both vaccinations. Noninferiority was
eclared if the lower limit of the 2-sided 95% CI for the GMR  was
reater than 0.5 (2-fold criterion). This value was selected based on
atching immunogenicity to efﬁcacy results from several infant
-valent Pneumococcal polysaccharide conjugate vaccine (PCV) or
-valent PCV efﬁcacy trials [9]. A secondary analysis assessed sta-
istically signiﬁcantly greater or lower responses; a statistically
reater response was declared if the lower limit of the 95% CI for
he GMR  was >1.0, and a statistically lower response was  declared
f the upper limit of the 95% CI for the GMR  was  <1.0.
Reverse cumulative distribution curves (RCDC) for key compar-
sons were generated to permit comparisons of immune response
hroughout the full range of OPA responses
.7.3. Safety analyses
Comparisons of the incidence of local reactions and systemic
vents between vaccine groups were performed with correspond-
ng 95% CIs and p-values based on Chan and Zhang methodology
10].
. Results
.1. Baseline characteristics and disposition of subjects
A total of 405 subjects 60–64 years of age at enrollment in the
nitial study participated in the extension study. Of those, 216 had
eceived PCV13 in the initial study and were randomized to receive
CV13 (N = 108) or PPSV23 (N = 108) in the extension study, and 189
ad received PPSV23 in the initial study and received PPSV23 in
he extension study, with all being evaluable. Additionally, 214 of
ubjects 50–59 years of age at initial study enrollment participated
n the extension study and received a second PCV13 vaccination,
ith 211 being evaluable. In total, 50.1% of subjects who  received
accination 1 in the initial study returned for this extension study
Table 1, Fig. 1).
The mean ages of subjects in the 60–64 year age group and in the
0–59 year age group were 65.3 years and 57.9 years, respectively,
t vaccination 2. The mean intervals since initial vaccination were
.7 (range 3.6–3.9) and 3.5 (range 3.3–3.6) years, respectively.
The race and ethnicity of subjects was similar across the
otal study population with the majority of subjects being white
94.7–98.1%). In adults aged 60–64 years, more females were vac-
inated in the PCV13/PCV13 and PPSV23/PPSV23 groups (57.4% and
4.0% respectively) compared to the PCV13/PPSV23 group (50.0%),
nd in the younger cohort, who all received PCV13/PCV13, 63.1% of
ubjects were female (Table 1).
In the older and younger age groups 25.9% and 19.2%, respec-
ively, reported chronic underlying diseases.
.2. Immune responses
.2.1. PPSV23 following initial PCV13 (PCV13/PPSV23) compared
o initial PPSV23
OPA geometric mean titers (GMTs) following PPSV23 adminis-
ered after PCV13 were statistically signiﬁcantly greater for 10 of 13
erotypes (1, 3, 5, 6A, 6B, 7F, 18C, 19A, 19F, 23F) and non-inferior for
he remainder (4, 9V, 14), when compared to responses following
nitial PPSV23 administered in the previous study (Table 2). Ta
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Table 3
Pneumococcal OPA GMTs following revaccination with PCV13 in 50–59 year old subjects initially vaccinated with PCV13 and comparison of pneumococcal OPA GMTs
following vaccination with 13vPnC/13vPnC in 60–64 year old subjects and 50–59 year old subjects.
Serotype PCV13/PCV13 vs PCV13 (Adults 50–59 years of age) PCV13/PCV13 (Adults 50–59 years of age vs. Adults 60–64 years of age)
PCV13/PCV13
na = 181–202
PCV13
na = 181–202
Ratio 50–59 years of
age na = 196–205
60–64 years of
age na = 100–104
Ratio
GMTb GMTb GMT  ratioc,d
(95% CI)
GMTb GMTb GMT  ratioc
(95% CI)
1 296 198 1.5 (1.20–1.86) 292 334 0.9 (0.63–1.22)
3  85 91 0.9 (0.80–1.08) 83 87 1.0 (0.73–1.26)
4  1685 2817 0.6 (0.49–0.73) 1657 1175 1.4 (1.07–1.86)
5  291 235 1.2 (1.02–1.50) 293 276 1.1 (0.71–1.58)
6Ae 3143 4347 0.7 (0.6–0.87) 3104 2064 1.5 (1.05–2.16)
6B  4886 3085 1.6 (1.29–1.95) 4885 4184 1.2 (0.88–1.54)
7F  1659 1596 1.0 (0.83–1.30) 1654 1223 1.4 (1.06–1.73)
9V  1492 1933 0.8 (0.61–0.98) 1421 770 1.8 (1.23–2.77)
14  1278 865 1.5 (1.15–1.90) 1186 1031 1.1 (0.85–1.55)
18C  2156 1742 1.2 (0.96–1.59) 2066 1918 1.1 (0.79–1.46)
19A  1048 959 1.1 (0.94–1.27) 1039 789 1.3 (1.01–1.72)
19F  1182 633 1.9 (1.51–2.32) 1171 958 1.2 (0.88–1.70)
23F  1188 563 2.1 (1.63–2.73) 1158 867 1.3 (0.90–1.99)
a n = Number of subjects with determinate OPA titer for the speciﬁed serotype.
b GMTs calculated using all evaluable subjects with data for a given blood draw.
c Ratio of GMTs calculated by back transforming the mean difference between vaccine groups on the logarithmic scale.
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.2.2. PCV13/PPSV23 compared to initial PCV13
OPA GMTs following PPSV23 administered after PCV13 were
tatistically signiﬁcantly greater for 7 of 13 serotypes (1, 3, 5, 7F,
4, 19A, 19F) and met  non-inferiority criteria for 4 of the remaining
 serotypes (4, 6B, 18C, 23F) when compared to responses follow-
ng initial PCV13 administered in the previous study (Table 2). The
PA GMTs were signiﬁcantly lower for 3 serotypes (4, 6A, 9V);
onetheless, the 95% CI upper bounds for 2 of these serotypes (4
nd 9V) were ≥0.91 suggesting generally comparable responses
hen comparing the ﬁrst and second vaccine administrations. Only
he serotype 6A response following PPSV23 administration was
learly lower than after initial PCV13, reﬂecting the absence of this
erotype in PPSV23 (Table 2).
.2.3. PCV13/PCV13 compared to initial PCV13
OPA GMTs following 2 administrations of PCV13 were statis-
ically signiﬁcantly greater compared to a single administration
f PCV13 for 7 of 13 serotypes (1, 5, 6B, 14, 19A, 19F, 23F) in
dults 60–64 years of age (Table 2), and 6 of 13 serotypes (1, 5,
B, 14, 19F, 23F) in adults 50–59 years of age (Table 3). Responses
o the remaining serotypes were largely non-inferior, although 3
erotypes (4, 6A, 9V) yielded statistically inferior responses in the
ounger age group.
.2.4. PPSV23/PPSV23 compared to initial PPSV23
OPA GMTs following 2 doses of PPSV23 were statistically signif-
cantly lower for 9 of the 13 serotypes (3, 4, 5, 6A, 9V, 14, 18C, 19F,
3F), and non-inferior for the remaining 4 serotypes (1, 6B, 7F, 19A)
Table 4).
.2.5. PCV13/PPSV23 compared to PPSV23/PPSV23
OPA GMTs following administration of PPSV23 to persons
ho had previously received PCV13 were statistically signiﬁcantly
reater for all serotypes compared to the responses to PPSV23 given
o persons who had previously received PPSV23 (Table 4)..2.6. PCV13/PCV13 compared to PPSV23/PPSV23
OPA GMTs following a second dose of PCV13 were statisti-
ally signiﬁcantly greater for all common serotypes compared to
esponses following a second dose of PPSV23 (Table 4).r own control across time and GMTs are derived for subjects with data at both time
3.2.7. PCV13/PCV13 in younger adults compared to PCV13/PCV13
in older adults
OPA GMTs after 2 doses of PCV13 in the younger age group were
statistically signiﬁcantly greater for 5 serotypes (4, 6A, 7F, 9V, 19A)
(Table 3).
3.3. Population responses
RCDCs showing the population anti-pneumococcal OPA
responses in adults 60–64 years of age for the vaccination
sequences PCV13/PCV13, PCV13/PPSV23, and PPSV23/PPSV23
conﬁrm the results obtained when comparing OPA GMTs (Sup-
plemental Figs. S1, S2, S3). Depending on serotype, responses
throughout the vaccinated population were higher or comparable
following administration of PPSV23 or PCV13 given after an initial
administration of PCV13. In contrast, population responses were
consistently lower following 2 consecutive doses of PPSV23.
3.4. Safety
Local reactions were generally mild across all groups. Incidences
of local reactions in subjects receiving 2 sequential doses of PCV13,
or PCV13 followed by PPSV23, were generally lower than for sub-
jects receiving 2 doses of PPSV23 (Table 5). An increase in local
reactions was seen after a second dose of PPSV23 compared to a
ﬁrst (Table 5). Muscle pain, fatigue, and headache were the most
common systemic events after each vaccination (Table 5). Fever
was  rare and no severe fever was reported. Most adverse events
(AEs) were conditions commonly observed among older adults, and
no vaccine related serious adverse events (SAEs) or deaths were
reported.
4. Discussion
Although the incidence and mortality of pneumococcal disease
increase with age among older adults, the current recommended
use of PPSV23 does not allow for maintenance of the vaccine-
elicited protective immune response over the period of risk. This
vaccine is not generally recommended for adults 50–64 years
of age and, in the United States, only a single administration is
L.A. Jackson et al. / Vaccine 3
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recommended for adults ≥65 years [2,3,11]. Although not invari-
antly observed, re-immunization with PPSV23 has been repeatedly
shown to elicit lower antibody responses following revaccination,
compared to the responses after initial administration [11,12].
Of interest, similar observations have been made with other free
polysaccharide vaccines, such as Neisseria meningitidis capsular
polysaccharide vaccines [4,14,15]. The underlying mechanism for
the blunting of the immune response with revaccination is not fully
understood, but may  be due to the loss of memory B cells upon
initial or follow-on administration of free polysaccharides [16–18].
By contrast, an efﬁcient recall response is seen with PCVs like
PCV13 in which the polysaccharide is covalently attached to an
immunological “carrier” protein converting the T cell-independent
immune response elicited by PPSV23 to a T cell-dependent immune
response [17–20]. Therefore, PCV13 may  induce a qualitatively dif-
ferent immune response than that elicited by PPSV23, resulting in
immunological memory and an improved immune response upon
subsequent vaccine administration of PCV13 or PPSV23 with the
potential for re-immunization to provide protection for a lifetime
of risk. ACIP recently recommended that certain immunocompro-
mized populations be vaccinated with PCV13 ﬁrst followed by a
dose of PPSV23 [21].
In this study, subjects in both age groups who received PCV13 in
the previous study generally had robust responses to either PCV13
or PPSV23 given in the current study. Among persons who received
a second dose of PCV13, responses to the second vaccination were
generally at least comparable to initial PCV13 responses and sta-
tistically signiﬁcantly greater for many of the serotypes. Among
persons who received PCV13 in the original study and PPSV23 in
this extension study, the responses following the PPSV23 were
signiﬁcantly greater for most of the serotypes common to both vac-
cines than those observed in persons who  received an initial dose
of PPSV23 in the original study.
The recall immune responses seen after re-vaccination with
PCV13 in the current study are in contrast to previously reported
results. In previous studies, neither administration of a second dose
of PCV13 one year after an initial dose of PCV13 nor a dose of PPSV23
administered 3–6 months after a dose of PCV7 demonstrated an
apparent immunological recall [22–25]. It is possible that a longer
interval between PCV13 administration and a second dose of PCV13
or a dose of PPSV23 is required to optimize immune responses
to subsequent doses of pneumococcal vaccine after an initial dose
of conjugated vaccine. These results support the perspective that
the conjugate vaccine is capable of eliciting polysaccharide-speciﬁc
immunological memory.
In contrast, administration of a second dose of PPSV23 to per-
sons who had received PPSV23 in the original study led to notably
lower immune responses than those observed following the ini-
tial PPSV23. The lack of immunological memory elicited by PPSV23
stands in contrast to the apparent memory elicited by PCV13,
and reﬂects previously reported observations with similar vaccines
[26]. The immunological advantage of the PCV compared to the
free (unconjugated) polysaccharide vaccine is most notable when
comparing the OPA responses after 2 doses of PCV13 with those
following 2 doses of PPSV23. An OPA threshold for protection has
not been identiﬁed, but the population responses as reﬂected by
the RCDCs demonstrate the immunologic advantage of the PCV13
throughout the full distribution of OPA responses for a number of
serotypes. Hence, whatever the threshold, PCV13 alone or as a suc-
cessive dose is likely to improve protection, compared to single or
successive doses of PPSV23 for serotypes common to both vaccines.
Finally, responses after 2 PCV13 doses in 50–59 year olds were
noninferior to the responses in the older age group and statistically
signiﬁcantly greater for 5 serotypes, demonstrating a not unex-
pected greater immune response in younger compared to older
adults.
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Table 5
Local reactions and systemic events reported up to day 14 after vaccination 1 and vaccination 2.
Adults 60–64 years of age Adults 50–59 years of age
PPSV23/PPSV23 vs. PPSV23 PCV13/PPSV23 vs. PCV13 PCV13/PCV13 vs. PCV13 PCV13/PCV13 vs. PCV13
PPSV23/PPSV23% PPSV23% Differenced
(95% CI)
PCV13/PPSV23% PCV13% Differenced
(95% CI)
PCV13/PCV13% PCV13% Differenced
(95% CI)
PCV13/PCV13% PCV13% Differenced
(95% CI)
Local reactions
Rednessa Any 30.5 13.6 16.9 (3.0;29.8)28.0 20.0 8.0 (−14.2;29.0)2 .6 26.5 −5.9 (−19.8;8.7)26.5 18.4 8.2 (−5.8;21.5)
Mild  24.1 9.3 14.8 (1.3;27.3)17.4 13.0 4.3 (−18.1;26.1)20.6 23.5 −2.9 (−16.1;10.5)23.4 17.0 6.4 (−7.6;19.9)
Moderate  16.3 4.1 12.2 (0.7;22.8)14.3 9.5 4.8 (−16.4;25.1)6.1 9.1 −3.0 (−16.5;10.8)2.6 2.6 0.0 (−8.5;8.5)
Severe  4.4 0.0 4.4 (−2.9;11.4)4.8 4.8 0.0 (−14.8;14.8)0.0 0.0 0.0 (−5.9;5.9) 0.0 2.6 −2.6 (−9.4;4.4)
Swelling Any  31.0 12.1 19.0 (6.1;30.5)26.9 15.4 11.5 (−8.7;30.1)24.3 32.4 −8.1 (−26.3;11.0)24.5 26.5 −2.0 (−15.3;11.3)
Mild  18.9 11.3 7.5 (−4.4;18.9)24.0 8.0 16.0 (−3.6;33.2)17.1 25.7 −8.6 (−24.7;8.4)22.4 26.5 −4.1 (−17.7;9.9)
Moderate  16.3 2.0 14.3 (3.5;23.9) 9.5 9.5 0.0 (−19.1;19.1)1 .8 14.7 −2.9 (−20.0;14.4)0.0 5.4 −5.4 (−13.7;3.4)
Severe  2.3 0.0 2.3 (−3.8;8.2) 4.8 0.0 4.8 (−7.6;16.3)0.0 0.0 0.0 (−5.9;5.9) 0.0 0.0 0.0 (−5.0;5.0)
Painb Any 88.3 78.1 10.2 (3.1;16.9)86.3 84.9 1.4 (−9.1;11.8)77.8 81.9 −4.2 (−14.6;6.5)95.2 93.2 2.0 (−2.5;6.6)
Mild  83.8 73.5 10.3 (2.1;18.1)86.4 81.8 4.5 (−7.1;15.9)76.5 80.9 −4.4 (−15.4;6.9)2.8 90.6 2.2 (−3.8;8.1)
Moderate  52.4 28.6 23.8 (9.4;36.7)45.2 29.0 16.1 (−2.9;33.2)3.8 33.3 −9.5 (−23.6;5.4)56.5 35.5 21.0 (6.2;34.5)
Severe  12.2 8.2 4.1 (−6.2;14.0)17.4 4.3 13.0 (−3.0;27.0)0.0 0.0 0.0 (−5.9;5.9) 0.0 5.4 −5.4 (−13.7;3.4)
Limitation  of arm
movementc
Any 47.2 30.6 16.7 (3.5;28.9)37.9 24.1 13.8 (−9.4;35.2)6.2 35.7 −9.5 (−24.9;6.7)52.9 50.0 2.9 (−7.7;13.3)
Mild  45.7 30.0 15.7 (2.4;28.1)34.5 24.1 10.3 (−12.0;31.3)22.0 34.1 −12.2 (−28.3;5.1)47.0 47.0 0.0 (−11.9;11.9)
Moderate  2.3 0.0 2.3 (−3.8;8.2)13.6 0.0 13.6 (−3.0;28.0)3.1 3.1 0.0 (−5.8;5.8) 5.3 2.6 2.6 (−4.4;9.4)
Severe  8.3 4.2 4.2 (−4.7;12.7)10.0 0.0 10.0 (−5.9;54.0)0.0 0.0 0.0 (−5.9;5.9) 2.6 2.6 0.0 (−8.3;8.3)
Any  local reactione 88.7 79.7 9.0 (2.4;15.4)89.3 86.7 2.7 (−7.2;12.4)82.4 81.1 1.4 (−8.3;11.0)95.4 94.7 0.7 (−3.8;5.1)
Systemic  Events
Fever
Any (≥38 ◦C) 2.3 9.1 −6.8 (−16.8;3.7)4.8 0.0 4.8 (−7.6;16.3)0.0 0.0 0.0 (−5.9;5.9) 2.6 0.0 2.6 (−4.4;9.4)
Mild  (≥38 ◦C but
<38.5 ◦C)
2.3 2.3 0.0 (−7.5;7.5) 4.8 0.0 4.8 (−7.6;16.3)0.0 0.0 0.0 (−5.9;5.9) 2.6 0.0 2.6 (−4.4;9.4)
Moderate  (≥38.5 ◦C
but  <39 ◦C)
0.0 0.0 0.0 (−4.4;4.4) 0.0 0.0 0.0 (−8.9;8.9) 0.0 0.0 0.0 (−5.9;5.9) 0.0 0.0 0.0 (−5.0;5.0)
Severe  (≥39 ◦C but
≤40 ◦C)
0.0 0.0 0.0 (−4.4;4.4) 0.0 0.0 0.0 (−8.9;8.9) 0.0 0.0 0.0 (−5.9;5.9) 0.0 0.0 0.0 (−5.0;5.0)
>40 ◦C 0.0 6.8 −6.8 (−14.8;1.8)0.0 0.0 0.0 (−8.9;8.9) 0.0 0.0 0.0 (−5.9;5.9) 0.0 0.0 0.0 (−5.0;5.0)
Fatigue  56.4 64.9 −8.5 (−19.2;2.5)68.6 68.6 0.0 (−13.3;13.3)49.1 62.3 −13.2 (−27.5;2.0)65.6 65.6 0.0 (−10.7;10.7)
Headache  57.3 61.0 −3.7 (−15.4;8.3)52.4 54.8 −2.4 (−18.9;14.4)37.2 51.2 −14.0 (−27.2;0.6)1.4 72.7 −11.4 (−21.3;−0.9)
Chills  32.8 25.9 6.9 (−7.5;20.8)26.7 33.3 −6.7 (−24.5;12.0)22.2 22.2 0.0 (−13.6;13.6)22.6 24.5 −1.9 (−15.1;11.5)
Rash  32.7 9.1 23.6 (9.5;36.1)17.2 27.6 −10.3 (−29.4;10.0)24.2 12.1 12.1 (−2.9;25.8)7.3 9.8 −2.4 (−15.2;10.5)
Vomiting  2.3 0.0 2.3 (−3.8;8.2) 4.8 0.0 4.8 (−7.6;16.3)6.5 3.2 3.2 (−5.3;11.4)7.1 7.1 0.0 (−10.0;10.0)
Decreased  appetite 21.6 19.6 2.0 (−9.8;13.6)34.5 31.0 3.4 (−12.2;18.7)14.7 20.6 −5.9 (−21.8;10.7)26.4 28.3 −1.9 (−15.1;11.5)
New  generalized muscle
pain
70.5 57.9 12.6 (2.2;22.6)71.7 56.5 15.2 (−0.1;29.3)50.0 47.7 2.3 (−15.9;20.2)67.8 69.0 −1.1 (−12.8;10.5)
Aggravated  generalized
muscle  pain
40.0 25.0 15.0 (0.1;28.9)38.7 32.3 6.5 (−9.5;21.6)22.9 22.9 0.0 (−19.1;19.1)36.1 42.6 −6.6 (−20.5;7.8)
New  generalized joint pain 23.2 25.0 −1.8 (−12.4;9.0)20.7 31.0 −10.3 (−21.9;2.5)24.3 21.6 2.7 (−13.3;18.4)31.5 35.2 −3.7 (−18.0;10.8)
Aggravated  generalized
joint  pain
17.0 11.3 5.7 (−5.7;16.6)25.0 20.8 4.2 (−11.2;18.9)16.7 19.4 −2.8 (−18.9;13.7)25.0 25.0 0.0 (−14.1;14.1)
Any  systemic eventf 86.4 84.8 1.5 (−4.9;7.9)82.8 87.5 −4.7 (−15.6;6.5)77.6 79.1 −1.5 (−13.5;10.6)88.3 92.0 −3.6 (−8.8;1.6)
a Redness and swelling were categorized as absent if <2.5 cm,  mild if ≥2.5 cm and ≤5.0 cm, moderate if >5.0 cm and ≤10.0 cm,  and severe if >10.0 cm.
b If pain at the injection site was present, subjects were asked to enter the severity as mild if the symptom was easily tolerated, moderate if there was  discomfort sufﬁcient to interfere with usual activity, and severe if the pain
was  incapacitating.
c If limitation of arm movement was present, subjects were asked to enter the severity as mild if there was some limitation of arm movement, moderate if the subject was unable to move his or her arm above the head but able
to  move it above the shoulder, and severe if the subject was  unable to move the arm above the shoulder.
d Difference in proportions expressed as a percentage.
e Any local reaction = any pain, any swelling, any redness, or any limitation of arm movement.
f Any systemic event = any fever ≥38 ◦C, any fatigue, any headache, any chills, any rash, any vomiting, any decreased appetite, any new or aggravated generalized muscle pain, and any new or aggravated joint pain.
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An acceptable safety proﬁle was seen when PCV13 was  followed
.5–4 years later by PCV13 or PPSV23, irrespective of subject age.
ubsequent vaccination with PPSV23 gave rise to more local reac-
ions in those previously administered PCV13 or PPSV23 than did
evaccination with PCV13.
A potential limitation is that the study was a non-prospective
pen label extension of a reported parent study [5]. However, all
erological evaluations remained blinded throughout all stages of
he study, and vaccine allocation in subjects aged 60–64 years
as maintained through an electronic randomization system. Sub-
ects that returned for the extension study did not differ in terms
f baseline demographics, medical history or response to initial
accination, when compared to subjects that did not return. The
tudy also did not include a study arm evaluating the sequence
f PPSV23 followed by PCV13 at a 3.5–4 year interval to evaluate
he potential longer term impact of PPSV23 on subsequent PCV13
mmune response. However, PPSV23 has been shown to dramati-
ally decrease response to subsequent PCV7 or PCV13 administered
 year later and results from this study demonstrate that the neg-
tive impact of PPSV23 on subsequent PPSV23 persists for at least
.5–4 years, consistent with the inability of this T cell indepen-
ent vaccine to prompt a recall response to antigens in common
19,20,23,27].
. Conclusion
The present study documents the potential advantage of ini-
ial PCV administration, which permits the establishment of an
mmune state that results in appropriate recall responses upon sub-
equent immunization with either PCV13 or PPSV23. The study
urther demonstrates that PCV13 in a younger adult popula-
ion results in higher responses compared to older adults. These
esponses can be sustained with a subsequent PCV13 dose when
elivered at an appropriate interval, and can likely be expanded
o include responses to the non-PCV13 serotypes with administra-
ion of PPSV23 later in life. Such an approach has the potential to
rovide protective immunity against signiﬁcant disease-associated
neumococcal serotypes throughout an extended at-risk period of
ater adult life.
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